Esomeprazole Magnesium

ApprovedWithdrawn

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Dyspepsia

Conditions

Dyspepsia

Trial Timeline

Dec 1, 2006 → Dec 1, 2006

NCT ID

NCT00443963

About Esomeprazole Magnesium

Esomeprazole Magnesium is a approved stage product being developed by AstraZeneca for Dyspepsia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00443963. Target conditions include Dyspepsia.

What happened to similar drugs?

2 of 15 similar drugs in Dyspepsia were approved

Approved (2) Terminated (2) Active (12)

✅esomeprazoleAstraZenecaApproved

✅Tegaserod and PlaceboNovartisApproved

🔄YM443Astellas PharmaPhase 3

🔄Cinitapride + domperidoneEisaiPhase 3

🔄Z-338Zeria PharmaceuticalPhase 3

🔄Imonogas + EspumisanJohnson & JohnsonPhase 3

🔄TegaserodNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00443963	Approved	Withdrawn	Dec 1, 2006	Dec 1, 2006	Dyspepsia
NCT00687245	Phase 1	Completed	Aug 1, 2006	May 1, 2008	Endoscopically-Proven GERD
NCT00637559	Approved	Completed	Mar 1, 2002	Apr 1, 2003	Barrett's Esophagus

Competing Products

20 competing products in Dyspepsia

See all competitors

Product	Company	Stage	Hype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + Placebo	Yuhan	Phase 2	27
YM443 + Placebo + Moxifloxacin	Astellas Pharma	Phase 1	29
YM443	Astellas Pharma	Phase 3	40
Cinitapride + domperidone	Eisai	Phase 3	40
Rabeprazole + Rabeprazole + Rabeprazole + Placebo	Eisai	Phase 2	35
Z-338	Zeria Pharmaceutical	Phase 3	40
Imonogas + Espumisan	Johnson & Johnson	Phase 3	40
esomeprazole	AstraZeneca	Approved	43
Tegaserod	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Tegaserod and Placebo	Novartis	Approved	35
Tegaserod	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Gabapentin + Placebo	Pfizer	Phase 3	32
Z-338	Zeria Pharmaceutical	Phase 2	35
Z-338	Zeria Pharmaceutical	Phase 2	35
Z-338	Zeria Pharmaceutical	Phase 2	35
Z-338 + Placebo	Zeria Pharmaceutical	Phase 3	40
Acotiamide hydrochloride hydrate + Placebo	Zeria Pharmaceutical	Phase 3	44